Zoetis Faces Securities Fraud Lawsuit Over Investor Losses
Investors who lost money on Zoetis Inc. (ZTS) shares have an opportunity to lead a securities fraud class action lawsuit. The complaint alleges the company made misleading statements.
Glancy Prongay Wolke & Rotter LLP has announced that investors who incurred losses on Zoetis Inc. (NYSE: ZTS) shares can lead a securities fraud class action lawsuit against the company. The lawsuit claims Zoetis made misleading statements to investors between January 14, 2025, and May 6, 2026.
The complaint alleges that Zoetis failed to disclose significant negative information. This includes sharply weakening veterinarian prescription growth and adoption of its canine pain treatment, Librela, following FDA safety warnings about serious neurological complications in dogs. The lawsuit also claims that Zoetis' Simparica Trio lost significant market share to a lower-priced competing canine parasiticide product in a slowing market.
Furthermore, the filing asserts that Zoetis' dermatology products, Apoquel and Cytopoint, lost substantial market share to a newly launched competing canine treatment. These alleged misrepresentations and omissions, according to the plaintiffs, meant that defendants' positive statements about the company's business and prospects lacked a reasonable basis.
Investors who wish to participate in the lawsuit or learn more are encouraged to contact Glancy Prongay Wolke & Rotter LLP by the lead plaintiff deadline of July 27, 2026. The law firm advises that no action is required at this time, and individuals can choose their own counsel or remain absent class members.
The legal action aims to recover losses for shareholders who experienced financial damage due to the alleged fraudulent conduct by Zoetis during the specified period.